|
1
|
Tan G, Zhang X, Feng H, Luo H and Wang Z:
The therapeutic effect of cytokine-induced killer cells on
pancreatic cancer enhanced by dendritic cells pulsed with K-ras
mutant peptide. Clin Dev Immunol. 2011:6493592011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wong HH and Lemoine NR: Biological
approaches to therapy of pancreatic cancer. Pancreatology.
8:431–461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ghanaati H, Alavian SM, Jafarian A, et al:
Imaging and imaging-guided interventions in the diagnosis and
management of hepatocellular carcinoma (HCC) - review of evidence.
Iran J Radiol. 9:167–177. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dhanasekaran R, Limaye A and Cabrera R:
Hepatocellular carcinoma: Current trends in worldwide epidemiology,
risk factors, diagnosis and therapeutics. Hepat Med. 4:19–37.
2012.PubMed/NCBI
|
|
5
|
Pardee AD and Butterfield LH:
Immunotherapy of hepatocellular carcinoma: Unique challenges and
clinical opportunities. Oncoimmunology. 1:48–55. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang HY and Wang RF: Enhancing cancer
immunotherapy by intracellular delivery of cell-penetrating
peptides and stimulation of pattern-recognition receptor signaling.
Adv Immunol. 114:151–176. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nowak M and Schmidt-Wolf IG: Natural
killer T cells subsets in cancer, functional defects in prostate
cancer and implications for immunotherapy. Cancers (Basel).
3:3661–3675. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y, Butterfield LH, Fu X, Song Z, Zhang
X, Lu C, Ding G and Wu M: Lentivirally engineered dendritic cells
activate AFP-specific T cells which inhibit hepatocellular
carcinoma growth in vitro and in vivo. Int J Oncol. 39:245–253.
2011.PubMed/NCBI
|
|
9
|
Condotta SA, Cabrera-Perez J, Badovinac VP
and Griffith TS: T-cell-mediated immunity and the role of TRAIL in
sepsis-induced immunosuppression. Crit Rev Immunol. 33:23–40. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S, Zhang H, Liu C, Jiao X, Liu D, Du
W, He Y, Zhang Z, Wu X, Wang J, et al: Human leukocyte
antigen-haploidentical donor-derived cytokine-induced killer cells
are safe and prolong the survival of patients with advanced
non-small cell lung cancer. Oncol Lett. 8:2727–2733.
2014.PubMed/NCBI
|
|
11
|
Wang M, Shi SB, Qi JL, Tang XY and Tian J:
S-1 plus CIK as second-line treatment for advanced pancreatic
cancer. Med Oncol. 30:7472013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Charoentong P, Angelova M, Efremova M,
Gallasch R, Hackl H, Galon J and Trajanoski Z: Bioinformatics for
cancer immunology and immunotherapy. Cancer Immunol Immunother.
61:1885–1903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sabado RL and Bhardwaj N: Directing
dendritic cell immunotherapy towards successful cancer treatment.
Immunotherapy. 2:37–56. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cui Y, Yang X, Zhu W, Li J, Wu X and Pang
Y: Immune response, clinical outcome and safety of dendritic cell
vaccine in combination with cytokine-induced killer cell therapy in
cancer patients. Oncol Lett. 6:537–541. 2013.PubMed/NCBI
|
|
15
|
Zhu H, Yang X, Li J, Ren Y, Zhang T, Zhang
C, Zhang J, Li J and Pang Y: Immune response, safety and survival
and quality of life outcomes for advanced colorectal cancer
patients treated with dendritic cell vaccine and cytokine-induced
killer cell therapy. Biomed Res Int. 2014:6038712014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Niu J, Ren Y, Zhang T, Yang X, Zhu W, Zhu
H, Li J, Li J and Pang Y: Retrospective comparative study of the
effects of dendritic cell vaccine and cytokine-induced killer cell
immunotherapy with that of chemotherapy alone and in combination
for colorectal cancer. Biomed Res Int. 2014:2147272014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Nussenzweig MC, Steinman RM, Gutchinov B
and Cohn ZA: Dendritic cells are accessory cells for the
development of anti-trinitrophenyl cytotoxic T lymphocytes. J Exp
Med. 152:1070–1084. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Salman B, Zhou D, Jaffee EM, Edil BH and
Zheng L: Vaccine therapy for pancreatic cancer. Oncoimmunology.
2:e266622013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tada F, Abe M, Hirooka M, Ikeda Y, Hiasa
Y, Lee Y, Jung NC, Lee WB, Lee HS, Bae YS, et al: Phase I/II study
of immunotherapy using tumor antigen-pulsed dendritic cells in
patients with hepatocellular carcinoma. Int J Oncol. 41:1601–1609.
2012.PubMed/NCBI
|
|
20
|
Ma Y, Xu YC, Tang L, Zhang Z, Wang J and
Wang HX: Cytokine-induced killer (CIK) cell therapy for patients
with hepatocellular carcinoma: Efficacy and safety. Exp Hematol
Oncol. 1:112012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martin CA, Kurkowski DL, Valentino AM and
Santiago-Schwarz F: Increased intracellular, cell surface and
secreted inducible heat shock protein 70 responses are triggered
during the monocyte to dendritic cell (DC) transition by cytokines
independently of heat stress and infection and may positively
regulate DC growth. J Immunol. 183:388–399. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu C, Suksanpaisan L, Chen YW, Russell SJ
and Peng KW: Enhancing cytokine-induced killer cell therapy of
multiple myeloma. Exp Hematol. 41:508–517. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Schmeel FC, Schmeel LC, Gast SM and
Schmidt-Wolf IG: Adoptive immunotherapy strategies with
cytokine-induced killer (CIK) cells in the treatment of
hematological malignancies. Int J Mol Sci. 15:14632–14648. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rettinger E, Glatthaar A, Abhari BA, et
al: SMAC mimetic BV 6 enables sensitization of resistant tumor
cells but also affects cytokine-induced killer (CIK) cells: A
potential challenge for combination therapy. Front Pediatr.
2:752014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jiang J, Wu C and Lu B: Cytokine-induced
killer cells promote antitumor immunity. J Transl Med. 11:832013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu H, Song J, Yang Z and Zhang X: Effects
of cytokine-induced killer cell treatment combined with FOLFOX4 on
the recurrence and survival rates for gastric cancer following
surgery. Exp Ther Med. 6:953–956. 2013.PubMed/NCBI
|
|
27
|
Zhong R, Han B and Zhong H: A prospective
study of the efficacy of a combination of autologous dendritic
cells, cytokine-induced killer cells and chemotherapy in advanced
non-small cell lung cancer patients. Tumour Biol. 35:987–994. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yuanying Y, Lizhi N, Feng M, Xiaohua W,
Jianying Z, Fei Y, Feng J, Lihua H, Jibing C, Jialiang L, et al:
Therapeutic outcomes of combining cryotherapy, chemotherapy and
DC-CIK immunotherapy in the treatment of metastatic non-small cell
lung cancer. Cryobiology. 67:235–240. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang YY, Wang YS, Liu T, Yang K, Yang GQ,
Liu HC, Wang SS and Yang JL: Efficacy study of CyberKnife
stereotactic radiosurgery combined with CIK cell immunotherapy for
advanced refractory lung cancer. Exp Ther Med. 5:453–456.
2013.PubMed/NCBI
|
|
30
|
Niu LZ, Li JL, Zeng JY, Mu F, Liao MT, Yao
F, Li L, Liu CY, Chen JB, Zuo JS, et al: Combination treatment with
comprehensive cryoablation and immunotherapy in metastatic
hepatocellular cancer. World J Gastroenterol. 19:3473–3480. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li W, Xu LP, Di Zhao L, Wang L, Zhang Y,
Gao QL and Mai L: Cytokine-induced killer cell therapy for advanced
pancreatic adenocarcinoma: A case report and review of the
literature. Oncol Lett. 5:1427–1429. 2013.PubMed/NCBI
|
|
32
|
Nakamoto Y, Mizukoshi E, Tsuji H, Sakai Y,
Kitahara M, Arai K, Yamashita T, Yokoyama K, Mukaida N, Matsushima
K, et al: Combined therapy of transcatheter hepatic arterial
embolization with intratumoral dendritic cell infusion for
hepatocellular carcinoma: Clinical safety. Clin Exp Immunol.
147:296–305. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jiang JT, Shen YP, Wu CP, Zhu YB, Wei WX,
Chen LJ, Zheng X, Sun J, Lu BF and Zhang XG: Increasing the
frequency of CIK cells adoptive immunotherapy may decrease risk of
death in gastric cancer patients. World J Gastroenterol.
16:6155–6162. 2010. View Article : Google Scholar : PubMed/NCBI
|
